A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA-2)
Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years.
The aim of the study is to see how safe, tolerable, and effective the study drug is.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
-
For USA participants, age criteria are 4 to < 18 years old, at the time of the administration of the first dose of study intervention. Non-USA participants age criteria are 2 to < 18 years old
-
Must have a confirmation of FOP diagnosis, as described in the protocol
-
At the time of enrollment, participants must weight:
- Cohort 1: more than 30 kg (or 66.1 pounds)
- Cohort 2: more than 30 kg (or 66.1 pounds)
- Cohort 3: less than or equal to 30 kg (or 66.1 pounds)
Key Exclusion Criteria:
- Cumulative Analog Joint Involvement Scale (CAJIS) score > 19 at the time of screening
- Participant has significant concomitant illness or history of significant illness, as described in the protocol
- Previous history or diagnosis of cancer
- Ongoing significant viral or bacterial illness, within 2 weeks of the first study drug administration
- History of severe respiratory compromise requiring oxygen, respiratory support
- Known history of cerebral vascular malformation
- Participants with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
- Participants with a known pre-existing medical history of a bleeding diathesis, as described in the protocol
- Participants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization
NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1: Adolescents
Participants aged 12 - 18 years old |
Administered per the protocol
Other Names:
|
|
Experimental: Cohort 2: Children
Children who are 4 to 12 years old (for non-US sites only 2 to 12 years old) |
Administered per the protocol
Other Names:
|
|
Experimental: Cohort 3: Children and Adolescents
Participants and Children aged 4 to 18 years old (for non-US sites only 2 to 18 years old) |
Administered per the protocol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Severity of TEAEs
Time Frame: Baseline to week 56
|
Baseline to week 56
|
|
Concentrations of functional garetosmab in serum
Time Frame: Through week 56
|
Through week 56
|
|
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
Time Frame: Baseline to week 56
|
Baseline to week 56
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of new HO lesions
Time Frame: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Occurrence of new HO lesions
Time Frame: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Number of clinician-assessed flare-ups
Time Frame: Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Occurrence of clinician-assessed flare-ups
Time Frame: Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Characteristics of menstrual cycles for female participants who reached menarche
Time Frame: Over 28 weeks and 56 weeks
|
Over 28 weeks and 56 weeks
|
|
|
Concentrations of total activin A in serum
Time Frame: Through week 56
|
Through week 56
|
|
|
Occurence of Anti-Drug Antibody (ADA) to garetosmab
Time Frame: Through week 56
|
Through week 56
|
|
|
Magnitude of ADA to garetosmab
Time Frame: Through week 56
|
Through week 56
|
|
|
Change from baseline in hearing function as assessed by audiometry
Time Frame: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Total volume of new Heterotopic Ossification (HO) lesions
Time Frame: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in total volume of HO lesions
Time Frame: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Tanner puberty scale
Time Frame: At week 28 and week 56
|
Tanner puberty scale or stages: Staging of sexual development is graded on a 5-point ordinal scale ranging from 1 (prepubertal) to 5 (adultlike) for female breast development, male external genitals, and pubic hair |
At week 28 and week 56
|
|
Height-for-age Z-Scores according to the World Health Organization (WHO) Growth Reference Data for Children
Time Frame: Through week 56
|
Participants 5-19 years of age Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance. |
Through week 56
|
|
Change from baseline in knee height
Time Frame: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Pediatric Quality of Life inventory (PedsQL) scores
Time Frame: At week 28 and week 56
|
Age-appropriate PedsQL Generic Core Scales will be used to measure HRQoL in children and adolescents. Response options include 5-point Likert scale (or 3-point Likert scale for the young children self-report) for each item asking about experience within the past week. Global scores are transformed to a 0 to 100 scale with higher scores indicating better quality of life. |
At week 28 and week 56
|
|
Acceptability or tolerability assessment via exit interview
Time Frame: Up to week 52
|
Each interview will be conducted by trained external interviewers following a semi-structured interview guide of questions for the participants about their overall experience in the trial. |
Up to week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Muscular Diseases
- Pathologic Processes
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Connective Tissue Diseases
- Carbohydrate Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Myositis
- Mucopolysaccharidoses
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- Myositis Ossificans
- Mucopolysaccharidosis IV
- Ossification, Heterotopic
Other Study ID Numbers
Other Study ID Numbers
- R2477-FOP-2413
- 2024-518415-19-01 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD Sharing Time Frame
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.